IP Library Granted Patent US 8,071,134
Granted Patent B2
US 8,071,134 · App. 11/663,047 · Granted Dec 6, 2011

Thyroid hormone analogs and methods of use

Assignees: Ordway Research Institute, Inc.; Albany College of Pharmacy
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,134
App. No.
11/663,047
Granted
Dec 6, 2011
Kind
B2
Abstract

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Claims (4)

1. A method for treating a condition amenable to treatment by inhibiting angiogenesis, said method comprising administering to a subject in need thereof an amount of an anti-angiogenesis agent effective for inhibiting angiogenesis in said subject, wherein said condition amenable to treatment by inhibiting angiogenesis is glioma, wherein said anti-angiogenesis agent is tetraiodothyroacetic acid (TETRAC), triiodothyroacetic acid (TRIAC), or combinations thereof, and wherein the agent effective for inhibiting angiogenesis acts at the cell surface and is conjugated via a covalent bond to a polymer selected from the group consisting of polyglycolide, polylactide, and co-polymers thereof.

2. The method of claim 1 , wherein the mode of administration of the anti-angiogenesis agent is parenteral, oral, rectal, topical, or combinations thereof.

3. The method of claim 1 , wherein the method further comprises administering one or more anti-angiogenesis therapies or chemotherapeutic agents to the subject.

4. The method of claim 1 , wherein the agent effective for inhibiting angiogenesis conjugated to a polymer is formulated into a nanoparticle, wherein said nanoparticle is less than 200 nm in size.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2014
From: ORDWAY RESEARCH INSTITUTE, INC.; ALBANY COLLEGE OF PHARMACY & HEALTH SCIENCES
To: NANOPHARMACEUTICALS LLC
Reel/Frame 032244/0192 →
CHANGE OF NAME Recorded Jun 8, 2011
From: ALBANY COLLEGE OF PHARMACY
To: ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES
Reel/Frame 026407/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2010
From: DAVIS, FAITH B.; DAVIS, PAUL J.
To: ORDWAY RESEARCH INSTITUTE, INC.
Reel/Frame 024150/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2010
From: MOUSA, SHAKER A.
To: ALBANY COLLEGE OF PHARMACY
Reel/Frame 024150/0926 →
Continuity (4)
Continuation In Part 10943072 · Sep 15, 2004
Provisional Application 60502721 · Sep 15, 2003
Provisional Application 60670534 · Apr 13, 2005
Related Publication 20080124280A1 · May 29, 2008